Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Evolution of Osteochondritis Dissecans of the Lateral Femoral Condyle Combined with Discoid Meniscus.

Bulgheroni E, Mattioli L, Bulgheroni P.

Joints. 2017 Jul 28;5(2):114-117. doi: 10.1055/s-0037-1603673. eCollection 2017 Jun.

2.

Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity.

Torri A, Carpi D, Bulgheroni E, Crosti MC, Moro M, Gruarin P, Rossi RL, Rossetti G, Di Vizio D, Hoxha M, Bollati V, Gagliani C, Tacchetti C, Paroni M, Geginat J, Corti L, Venegoni L, Berti E, Pagani M, Matarese G, Abrignani S, de Candia P.

J Biol Chem. 2017 Feb 17;292(7):2903-2915. doi: 10.1074/jbc.M116.769893. Epub 2017 Jan 11.

3.

Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.

Harari S, Elia D, Torre O, Bulgheroni E, Provasi E, Moss J.

Chest. 2016 Aug;150(2):e29-32. doi: 10.1016/j.chest.2016.02.654.

4.

Comparative Study of Collagen versus Synthetic-Based Meniscal Scaffolds in Treating Meniscal Deficiency in Young Active Population.

Bulgheroni E, Grassi A, Campagnolo M, Bulgheroni P, Mudhigere A, Gobbi A.

Cartilage. 2016 Jan;7(1):29-38. doi: 10.1177/1947603515600219.

5.

Posterolateral rotatory instability of the knee after arthroscopic subtotal lateral meniscectomy: a case report.

Bulgheroni E, Bulgheroni P.

Joints. 2014 Jul 8;2(2):93-6. eCollection 2014 Apr-Jun.

6.

Long-term outcomes of medial CMI implant versus partial medial meniscectomy in patients with concomitant ACL reconstruction.

Bulgheroni E, Grassi A, Bulgheroni P, Marcheggiani Muccioli GM, Zaffagnini S, Marcacci M.

Knee Surg Sports Traumatol Arthrosc. 2015 Nov;23(11):3221-7. doi: 10.1007/s00167-014-3136-9. Epub 2014 Jul 4.

PMID:
24990662
7.

Intracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation.

de Candia P, Torri A, Gorletta T, Fedeli M, Bulgheroni E, Cheroni C, Marabita F, Crosti M, Moro M, Pariani E, Romanò L, Esposito S, Mosca F, Rossetti G, Rossi RL, Geginat J, Casorati G, Dellabona P, Pagani M, Abrignani S.

PLoS One. 2013 Sep 26;8(9):e75348. doi: 10.1371/journal.pone.0075348. eCollection 2013.

8.

Polyurethane scaffold for the treatment of partial meniscal tears. Clinical results with a minimum two-year follow-up.

Bulgheroni P, Bulgheroni E, Regazzola G, Mazzola C.

Joints. 2014 Mar 21;1(4):161-6. eCollection 2013 Oct-Dec.

9.

Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors.

Busnelli M, Bulgheroni E, Manning M, Kleinau G, Chini B.

J Pharmacol Exp Ther. 2013 Aug;346(2):318-27. doi: 10.1124/jpet.113.202994. Epub 2013 May 30.

10.

Mice heterozygous for the oxytocin receptor gene (Oxtr(+/-)) show impaired social behaviour but not increased aggression or cognitive inflexibility: evidence of a selective haploinsufficiency gene effect.

Sala M, Braida D, Donzelli A, Martucci R, Busnelli M, Bulgheroni E, Rubino T, Parolaro D, Nishimori K, Chini B.

J Neuroendocrinol. 2013 Feb;25(2):107-18. doi: 10.1111/j.1365-2826.2012.02385.x.

PMID:
22967062
11.

Arthroscopic collagen meniscus implantation for partial lateral meniscal defects: a 2-year minimum follow-up study.

Zaffagnini S, Marcheggiani Muccioli GM, Bulgheroni P, Bulgheroni E, Grassi A, Bonanzinga T, Kon E, Filardo G, Busacca M, Marcacci M.

Am J Sports Med. 2012 Oct;40(10):2281-8. Epub 2012 Aug 20.

PMID:
22915481
12.

Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism.

Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V, Finardi A, Donzelli A, Pattini L, Rubino T, Parolaro D, Nishimori K, Parenti M, Chini B.

Biol Psychiatry. 2011 May 1;69(9):875-82. doi: 10.1016/j.biopsych.2010.12.022. Epub 2011 Feb 21.

PMID:
21306704
13.

Dual modulation of inward rectifier potassium currents in olfactory neuronal cells by promiscuous G protein coupling of the oxytocin receptor.

Gravati M, Busnelli M, Bulgheroni E, Reversi A, Spaiardi P, Parenti M, Toselli M, Chini B.

J Neurochem. 2010 Sep 1;114(5):1424-35. doi: 10.1111/j.1471-4159.2010.06861.x. Epub 2010 Jun 14.

14.

Follow-up of collagen meniscus implant patients: clinical, radiological, and magnetic resonance imaging results at 5 years.

Bulgheroni P, Murena L, Ratti C, Bulgheroni E, Ronga M, Cherubino P.

Knee. 2010 Jun;17(3):224-9. doi: 10.1016/j.knee.2009.08.011. Epub 2009 Oct 2.

PMID:
19800801
15.

New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses.

Rusconi S, Lo Cicero M, Viganò O, Sirianni F, Bulgheroni E, Ferramosca S, Bencini A, Bianchi A, Ruiz L, Cabrera C, Martinez-Picado J, Supuran CT, Galli M.

Molecules. 2009 May 22;14(5):1927-37. doi: 10.3390/molecules14051927.

16.

Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol.

Bulgheroni E, Bandera A, Galli M, Gori A, Rusconi S.

AIDS Res Hum Retroviruses. 2005 Sep;21(9):815-9.

PMID:
16218807
17.

Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy.

Lo Cicero M, Bulgheroni E, Soster F, Viganò O, Cicconi P, Galli M, Rusconi S.

J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):238-41. No abstract available.

PMID:
16186745
18.

Efficacy and tolerability of multiple drug therapy in HIV-infected children.

Viganò A, Schneider L, Giacomet V, Bianchi R, Cicero ML, Soster F, Bulgheroni E, Rusconi S.

J Infect. 2005 Jun;50(5):404-11.

19.

Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.

Bulgheroni E, Citterio P, Croce F, Lo Cicero M, Viganò O, Soster F, Chou TC, Galli M, Rusconi S.

J Antimicrob Chemother. 2004 Mar;53(3):464-8. Epub 2004 Feb 12.

PMID:
14963061
20.

Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility.

Bulgheroni E, Croce F, Citterio P, Viganò O, Visonà R, Sala E, Galli M, Rusconi S.

J Clin Virol. 2004 Jan;29(1):27-32.

PMID:
14675866
21.

Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects.

Rusconi S, Bulgheroni E, La Seta Catamancio S, Croce F, Lo Cicero M, Citterio P, Galli M.

J Antimicrob Chemother. 2002 Feb;49(2):427-9. No abstract available.

22.

Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

Rusconi S, La Seta Catamancio S, Citterio P, Bulgheroni E, Kurtagic S, Galazzi M, Croce F, Moroni M, Galli M.

Antivir Ther. 2001 Mar;6(1):41-6.

PMID:
11417760
23.

In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.

Rusconi S, Merrill DP, La Seta Catamancio S, Citterio P, Bulgheroni E, Croce F, Chou TC, Yang OO, Herrmann SH, Galli M, Hirsch MS.

Antivir Ther. 2000 Sep;5(3):199-204.

PMID:
11075940
24.

Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.

Rusconi S, La Seta Catamancio S, Citterio P, Bulgheroni E, Croce F, Herrmann SH, Offord RE, Galli M, Hirsch MS.

J Virol. 2000 Oct;74(19):9328-32.

25.

Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.

Rusconi S, De Pasquale MP, Milazzo L, Kurtagic S, Bulgheroni E, Citterio P, Galazzi M, La Seta Catamancio S, Galli M.

Antivir Ther. 1998;3(4):203-7.

PMID:
10682139
26.

In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate.

Rusconi S, De Pasquale MP, Milazzo L, Bulgheroni E, Citterio P, Kurtagic S, d'Arminio-Monforte A, Galli M.

AIDS. 1997 Sep;11(11):1406-10. No abstract available.

PMID:
9302459
27.

Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.

Rusconi S, De Pasquale MP, Milazzo L, Moscatelli G, Bulgheroni E, Citterio P, d'Arminio-Monforte A, Moroni M, Galli M.

Antivir Ther. 1997 Jan;2(1):39-46.

PMID:
11322265
28.

Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.

Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, Violin M, Zanchetta N, Moroni M, Balotta C, Galli M.

Antivir Ther. 1996 Dec;1(4):211-9.

PMID:
11324823
29.

[Rheumatismm due to barbiturates an iatrogenic algodystrophy, in relation to studies of various cases].

Bulgheroni EM, Puricelli R, Ferrario A.

Minerva Med. 1977 Feb 4;68(6):369-74. Italian. No abstract available.

PMID:
300149

Supplemental Content

Loading ...
Support Center